Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YUTIQ Phase 4 Study in Chronic Non-Infectious Posterior Segment Uveitis
NCT05322070Phase 4Active, not recruiting
- Sponsor
- Alimera Sciences
- Start
- Jun 2022
- Primary completion
- Nov 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fluocinolone in posterior segment uveitis, sponsored by Alimera Sciences. Primary endpoints: Change in Best Corrected Visual Acuity at Month 6 and Change in Central Subfield Thickness at Month 6. Started Jun 2022; status: active, not recruiting.
02
Drugs
fluocinolone
03
Conditions
posterior segment uveitis
Beyond the preview
Go deeper on NCT05322070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05322070.